Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 3, 2010, Pages 369-378

  Valent, Peter ^a,b   Cerny Reiterer, Sabine ^a   Herrmann, Harald ^a,b   Mirkina, Irina ^a   George, Tracy I ^c   Sotlar, Karl ^d   Sperr, Wolfgang R ^a   Horny, Hans Peter ^e  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

^e Institute of Pathology   (Germany)

Author keywords

Mast cells; Phenotypic heterogeneity; Systemic mastocytosis

Indexed keywords

CD2 ANTIGEN; CD30 ANTIGEN; IMMUNOGLOBULIN E RECEPTOR; STEM CELL FACTOR RECEPTOR;

ANTIGEN EXPRESSION; CELL HETEROGENEITY; CELL MATURATION; HUMAN; MAST CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMIC MASTOCYTOSIS;

ANTIGENS, SURFACE; GENETIC HETEROGENEITY; HUMANS; LEUKEMIA, MAST-CELL; MAST CELLS; PATHOLOGY, MOLECULAR; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 78649498791     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.07.003     Document Type: Review

References (81)

1. S.J. Galli New insights into "the riddle of the mast cells": microenvironmental regulation of mast cell development and phenotypic heterogeneity Lab Invest 62 1990 5 33
2. P. Valent, C. Sillaber, and P. Bettelheim The growth and differentiation of mast cells Prog Growth Factor Res 3 1991 27 41
3. S.J. Galli New concepts about the mast cell N Engl J Med 328 1993 257 265
4. S.J. Galli, S. Nakae, and M. Tsai Mast cells in the development of adaptive immune responses Nat Immunol 6 2005 135 142
5. D.D. Metcalfe Mast cells and mastocytosis Blood 112 2008 946 956
6. A.S. Kirshenbaum, J.P. Goff, and S.W. Kessler Effects of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells J Immunol 148 1992 772 777
7. A.S. Kirshenbaum, J.P. Goff, and T. Semere Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13) Blood 94 1999 2333 2342
8. H. Agis, M. Willheim, and W.R. Sperr Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly- CD14- CD17- colony forming cell J Immunol 151 1993 4221 4227
9. P. Valent, E. Spanblöchl, and W.R. Sperr Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culture Blood 80 1992 2237 2245
10. H. Mitsui, T. Furitsu, and A.M. Dvorak Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand Proc Natl Acad Sci U S A 90 1993 735 739 (Pubitemid 23028940)
11. S.J. Galli, M. Tsai, and B.K. Wershil The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others Am J Pathol 142 1993 965 974
12. P. Valent The riddle of the mast cell: c-kit ligand as missing link? Immunol Today 15 1994 111 114
13. D.M. Anderson, S.D. Lyman, and A. Baird Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms Cell 63 1990 235 243
14. K. Miyazawa, D.A. Williams, and A. Gotoh Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form Blood 85 1995 641 649
15. H. Ochi, W.M. Hirani, and Q. Yuan T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro J Exp Med 190 1999 267 280
16. G.H. Schernthaner, A.W. Hauswirth, and M. Baghestanian Detection of differentiation- and activation-linked cell surface antigens on cultured mast cell progenitors Allergy 60 2005 1248 1255
17. P. Valent, L.K. Ashman, and W. Hinterberger Mast cell typing: demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes Blood 73 1989 1778 1785
18. P. Valent, and P. Bettelheim Cell surface structures on human basophils and mast cells: biochemical and functional characterization Adv Immunol 52 1992 333 423
19. H. Agis, W. Füreder, and H.C. Bankl Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes Immunology 87 1996 535 543
20. H. Saito, K. Matsumoto, and S. Okumura Gene expression profiling of human mast cell subtypes: an in silico study Allergol Int 55 2006 173 179
21. L. Escribano, A. Orfao, and B. Diaz-Agustin Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implication Blood 91 1998 2731 2736 (Pubitemid 28227522)
22. G.H. Schernthaner, J.H. Jordan, and M. Ghannadan Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells Blood 98 2001 3784 3792
23. L. Escribano, B. Díaz-Agustín, and C. Bellas Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis Leuk Res 25 2001 563 570
24. L Human Pathol 32 2001 545 552
25. P. Valent, G.H. Schernthaner, and W.R. Sperr Variable expression of activation-linked surface antigens on human mast cells in health and disease Immunol Rev 179 2001 74 81
26. P. Valent, O. Majdic, and D. Maurer Further characterization of surface membrane structures expressed on human basophils and mast cells Int Arch Allergy Appl Immunol 91 1990 198 203
27. P. Valent, D. Bevec, and D. Maurer Interleukin 4 promotes expression of mast cell ICAM-1 antigen Proc Natl Acad Sci U S A 88 1991 3339 3342
28. W.R. Sperr, H. Agis, and K. Czerwenka Differential expression of cell surface integrins on human mast cells and human basophils Ann Hematol 65 1992 10 16
29. W. Füreder, H. Agis, and M. Willheim Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells J Immunol 155 1995 3152 3160
30. M. Mayerhofer, K.J. Aichberger, and S. Florian Recognition sites for microbes and components of the immune system on human mast cells: relationship to CD antigens and implications for host defense Int J Immunopathol Pharmacol 20 2007 421 434
31. G. Marone, A. de Paulis, and G. Florio Are mast cells masters in HIV-1 infection? Int Arch Allergy Immunol 125 2001 89 95 (Pubitemid 32642046)
32. J.B. Sundstrom, D.M. Little, and F. Villinger Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells J Immunol 172 2004 4391 4401
33. M. Juremalm, and G. Nilsson Chemokine receptor expression by mast cells Chem Immunol Allergy 87 2005 130 144
34. M. Ghannadan, A.W. Hauswirth, and G.H. Schernthaner Detection of novel CD antigens on the surface of human mast cells and basophils Int Arch Allergy Immunol 127 2002 299 307 (Pubitemid 34522819)
35. H.P. Kiener, M. Baghestanian, and M. Dominkus Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis Arthritis Rheum 41 1998 233 245
36. Y. Kitamura Heterogeneity of mast cells and phenotypic change between subpopulations Annu Rev Immunol 7 1989 59 76
37. N. Ghildyal, D.S. Friend, and C.F. Nicodemus Reversible expression of mouse mast cell protease 2 mRNA and protein in cultured mast cells exposed to IL-10 J Immunol 151 1993 3206 3214
38. D.S. Friend, N. Ghildyal, and M.F. Gurish Reversible expression of tryptases and chymases in the jejunal mast cells of mice infected with Trichinella spiralis J Immunol 160 1998 5537 5545
39. K.F. Austen, and J.A. Boyce Mast cell lineage development and phenotypic regulation Leuk Res 25 2001 511 518
40. A.W. Hauswirth, L. Escribano, and A. Prados CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking Int J Immunopathol Pharmacol 21 2008 797 806
41. P. Valent, H.P. Horny, and L. Escribano Diagnostic criteria and classification of mastocytosis: a consensus proposal Leuk Res 25 2001 603 625
42. P. Valent, H.-P. Horny, and C.Y. Li Mastocytosis (mast cell disease). World Health Organization (WHO) classification of tumours. Pathology & Genetics E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman, Tumours of haematopoietic and lymphoid tissues vol. 1 2001 IARC Press Lyon France 291 302
43. P. Valent, C. Akin, and W.R. Sperr Mast cell proliferative disorders: current view on variants recognized by the World Health Organization Hematol Oncol Clin North Am 17 2003 1227 1241
44. P. Valent, C. Akin, and L. Escribano Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria Eur J Clin Invest 37 2007 435 453
45. H.P. Horny, C. Akin, and D.D. Metcalfe Mastocytosis (mast cell disease). World Health Organization (WHO) classification of tumours. Pathology & Genetics S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, Tumours of haematopoietic and lymphoid tissues vol. 2 2008 IARC Press Lyon France 54 63
46. K. Sotlar, H.P. Horny, and I. Simonitsch CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens Am J Surg Pathol 28 2004 1319 1325
47. M. Krokowski, K. Sotlar, and M.T. Krauth Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia Am J Clin Pathol 124 2005 560 568
48. H.P. Horny, C. Sillaber, and D. Menke Diagnostic value of immunostaining for tryptase in patients with mastocytosis Am J Surg Pathol 22 1998 1132 1140
49. H. Agis, M.T. Krauth, and I. Mosberger Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7 J Clin Pathol 59 2006 396 402
50. H.P. Horny, K. Sotlar, and F. Stellmacher The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers J Clin Pathol 59 2006 298 302
51. P. Valent, P. Samorapoompichit, and W.R. Sperr Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells Hematol J 3 2002 90 94
52. Arredondo AR, Gotlib J, Shier L, et-al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol, (in press).
53. C. Teodosio, A.C. García-Montero, and M. Jara-Acevedo Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes J Allergy Clin Immunol 125 2010 719 726
54. H.G. Drexler, and R.A.F. MacLeod Malignant hematopoietic cell lines: in vitro models for the study of mast cell leukemia Leukemia Res 27 2003 671 676
55. C. Akin, G. Fumo, and A.S. Yavuz A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib Blood 103 2004 3222 3225
56. A.C. Garcia-Montero, M. Jara-Acevedo, and C. Teodosio KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients Blood 108 2006 2366 2372
57. A. Pardanani, T.K. Kimlinger, and T.L. Reeder Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder Br J Haematol 120 2003 691 694
58. P. Valent Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders Blood Rev 23 2009 157 165
59. P. Valent, M. Ghannadan, and C. Akin On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts Eur J Clin Invest 34 S2 2004 41 52
60. M.T. Krauth, A. Böhm, and H. Agis Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils Exp Hematol 35 2007 108 116
61. S. Florian, K. Sonneck, and A.W. Hauswirth Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies Leuk Lymphoma 47 2006 207 222
62. C. Akin, K. Brockow, and C. D'Ambrosio Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit Exp Hematol 31 2003 686 692
63. Y. Zermati, P. De Sepulveda, and F. Feger Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms Oncogene 22 2003 660 664
64. K.V. Gleixner, M. Mayerhofer, and K.J. Aichberger PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects Blood 107 2006 752 759
65. J.D. Growney, J.J. Clark, and J. Adelsperger Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 Blood 106 2005 721 724
66. N.P. Shah, F.Y. Lee, and R. Luo Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis Blood 108 2006 286 291
67. K.V. Gleixner, M. Mayerhofer, and K. Sonneck Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT Haematologica 92 2007 1451 1459
68. J. Gotlib, C. Berubé, and J.D. Growney Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Blood 106 2005 2865 2870
69. D. Purtill, J. Cooney, and R. Sinniah Dasatinib therapy for systemic mastocytosis: four cases Eur J Haematol 80 2008 456 458
70. S. Verstovsek, A. Tefferi, and J. Cortes Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis Clin Cancer Res 14 2008 3906 3915
71. C. Ustun, C.L. Corless, and N. Savage Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V Leuk Res 33 2009 735 741
72. K.J. Aichberger, W.R. Sperr, and K.V. Gleixner Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis Eur J Clin Invest 38 2008 869 873
73. E.L. Sievers, R.A. Larson, and E.A. Stadtmauer Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244 3254
74. W.R. Sperr, S. Florian, and A.W. Hauswirth CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives Leuk Lymphoma 46 2005 1115 1120
75. L.G. Durrant, and I. Spendlove Immunization against tumor cell surface complement-regulatory proteins Curr Opin Investig Drugs 2 2001 959 966
76. C. Hafner, U. Samwald, and S. Wagner Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library J Invest Dermatol 119 2002 865 869
77. M. Popkov, S. Sidrac-Ghali, and V. Alakhov Epitope-specific antibody response to HT-1080 fibrosarcoma cells by mimotope immunization Clin Cancer Res 6 2000 3629 3635
78. R. Nunez-Lopez, L. Escribano, and G.H. Schernthaner Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis Br J Haematol 120 2003 257 265
79. H.C. Kluin-Nelemans, J.M. Oldhoff, and J.J. Van Doormaal Cladribine therapy for systemic mastocytosis Blood 102 2003 4270 4276
80. V. Schleyer, S. Meyer, and M. Landthaler Smoldering systemic mastocytosis: successful therapy with cladribine Hautarzt 55 2004 658 662
81. H.J. Bühring, P.J. Simmons, and M. Pudney The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multi- and unipotent progenitors Blood 94 1999 2343 2356